WO2026046172 - USE OF ANTI-FRα ANTIBODY-DRUG CONJUGATE AND VEGF ANTAGONIST IN TREATMENT OF TUMORS
National phase entry is expected:
Publication Number
WO/2026/046172
Publication Date
05.03.2026
International Application No.
PCT/CN2025/116967
International Filing Date
26.08.2025
Title **
[English]
USE OF ANTI-FRα ANTIBODY-DRUG CONJUGATE AND VEGF ANTAGONIST IN TREATMENT OF TUMORS
[French]
UTILISATION D'UN CONJUGUÉ ANTICORPS ANTI-FRα-MÉDICAMENT ET ANTAGONISTE DU VEGF DANS LE TRAITEMENT DE TUMEURS
[Chinese]
抗FRα抗体药物偶联物和VEGF拮抗剂在治疗肿瘤中的应用
Applicants **
BIO-THERA SOLUTIONS, LTD.
No.18 Luoxuan 2nd Road, International Bio-Island,
Guangzhou, Guangdong 510005, CN
Inventors
ZHONG, Di
A6-5FL., 11 Kaiyuan Rd., Science City, High-tech Industrial Development Zone
Guangzhou, Guangdong 510530, CN
FU, Ziyi
A6-5FL., 11 Kaiyuan Rd., Science City, High-tech Industrial Development Zone
Guangzhou, Guangdong 510530, CN
ZHANG, Xinlang
A6-5FL., 11 Kaiyuan Rd., Science City, High-tech Industrial Development Zone
Guangzhou, Guangdong 510530, CN
MAI, Siqi
A6-5FL., 11 Kaiyuan Rd., Science City, High-tech Industrial Development Zone
Guangzhou, Guangdong 510530, CN
TANG, Weijia
A6-5FL., 11 Kaiyuan Rd., Science City, High-tech Industrial Development Zone
Guangzhou, Guangdong 510530, CN
SONG, Shuqiang
A6-5FL., 11 Kaiyuan Rd., Science City, High-tech Industrial Development Zone
Guangzhou, Guangdong 510530, CN
LI, Shengfeng
A6-5FL., 11 Kaiyuan Rd., Science City, High-tech Industrial Development Zone
Guangzhou, Guangdong 510530, CN
Priority Data
202411190877.1
27.08.2024
CN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
CNIPA
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 1478 | |
| EPO | Filing, Examination | 10132 | |
| Japan | Filing | 588 | |
| South Korea | Filing | 574 | |
| USA | Filing, Examination | 3910 |
Total: 16682 USD
Abstract[English]
The present invention relates to use of an anti-FRα antibody-drug conjugate and a VEGF antagonist in the treatment of tumors. The treatment method comprises administering to a patient in need thereof an effective amount of the anti-FRα antibody-drug conjugate and the VEGF antagonist.[French]
La présente invention concerne l'utilisation d'un conjugué anticorps anti-FRα-médicament et d'un antagoniste du VEGF dans le traitement de tumeurs. La méthode de traitement comprend l'administration à un patient qui en a besoin d'une quantité efficace du conjugué anticorps anti-FRα-médicament et de l'antagoniste du VEGF.[Chinese]
本发明涉及抗FRα抗体药物偶联物和VEGF拮抗剂在治疗肿瘤中的应用，治疗方法包括向有需要的患者给药有效量的抗FRα抗体药物偶联物和VEGF拮抗剂。